

Acknowledgement of your transferred manuscript submission to RSC Advances - RA-ART-08-2021-006148

1 message

RSC Advances <onbehalf@manuscriptcentral.com>

Sat, Aug 14, 2021 at 10:40 AM

Reply-To: advances@rsc.org

To: m.zakki.fahmi@fst.unair.ac.id, zakkifahmi@gmail.com

Cc: aswandi.wibrianto-2016@fst.unair.ac.id, asw980223@gmail.com, dinar.fortuna.putri-2016@fst.unair.ac.id, satya.sakti@fst.unair.ac.id, m.zakki.fahmi@fst.unair.ac.id, zakkifahmi@gmail.com

14-Aug-2021

Dear Mr Fahmi:

TITLE: Naproxen release aspect from Boron-doped carbon nanodots as bifunctional agent on cancer therapy

Thank you for transferring your manuscript to RSC Advances, published by the Royal Society of Chemistry. This is an automatic acknowledgement that you have uploaded your files to our online submission system. Your manuscript ID is: RA-ART-08-2021-006148

Your manuscript will be passed to an editor for initial assessment as soon as possible. If there are any problems with your submission we will contact you.

All RSC Advances articles are published under an open access model, and the appropriate article processing charge (APC) will apply. Details of the APC and discounted rates can be found at <https://www.rsc.org/journals-books-databases/about-journals/rsc-advances/#charges-RSC-Advances>

Please note that RSC Advances now only publishes Paper and Review type articles. If your transferred submission is a Communication type article, this will be changed to a Paper type article if accepted for publication.

Please indicate the above manuscript ID when you contact us about this submission.

Do you have an ORCID iD? ORCID (Open Researcher and Contributor iD) is a unique researcher identifier that allows you to link your research output and other professional activities in a single record. We therefore encourage each researcher to sign up for their own ORCID account. Please edit your user account to link your ORCID iD or create a new one, ensuring that you have not linked your account to another researcher's ORCID iD. Please note that we are unable to do this on your behalf. If your article is accepted, you may choose to have your ORCID record updated automatically with details of the publication.

We already have the following information for authors of this manuscript: Wibrianto, Aswandi - <https://orcid.org/0000-0002-7746-7405>, Putri, Dinar Fortuna - No ORCID iD Available, Sakti, Satya Candara - No ORCID iD Available, Fahmi, Mochamad Zakki - <https://orcid.org/0000-0001-5430-9992>

This journal has a policy of sharing reviewer reports. Please note that the Editor's decision and copies of the reports will be shared with all reviewers who provide a recommendation on your manuscript.

Please contact us if we can be of any assistance.

Yours sincerely,

RSC Advances Editorial Office

advances@rsc.orgIf you need to contact the journal, please use the email address advances@rsc.org

DISCLAIMER:

This communication is from The Royal Society of Chemistry, a company incorporated in England by Royal Charter (registered number RC000524) and a charity registered in England and Wales (charity number 207890). Registered office: Burlington House, Piccadilly, London W1J 0BA. Telephone: +44 (0) 20 7437 8656.

The content of this communication (including any attachments) is confidential, and may be privileged or contain copyright material. It may not be relied upon or disclosed to any person other than the intended recipient(s) without the consent of The Royal Society of Chemistry. If you are not the intended recipient(s), please (1) notify us immediately by replying to this email, (2) delete all copies from your system, and (3) note that disclosure, distribution, copying or use of this communication is strictly prohibited.

Any advice given by The Royal Society of Chemistry has been carefully formulated but is based on the information available to it. The Royal Society of Chemistry cannot be held responsible for accuracy or completeness of this communication or any

attachment. Any views or opinions presented in this email are solely those of the author and do not represent those of The Royal Society of Chemistry. The views expressed in this communication are personal to the sender and unless specifically stated, this e-mail does not constitute any part of an offer or contract. The Royal Society of Chemistry shall not be liable for any resulting damage or loss as a result of the use of this email and/or attachments, or for the consequences of any actions taken on the basis of the information provided. The Royal Society of Chemistry does not warrant that its emails or attachments are Virus-free; The Royal Society of Chemistry has taken reasonable precautions to ensure that no viruses are contained in this email, but does not accept any responsibility once this email has been transmitted. Please rely on your own screening of electronic communication.

More information on The Royal Society of Chemistry can be found on our website: www.rsc.org

Decision on submission to RSC Advances - RA-ART-08-2021-006148

4 messages

RSC Advances <onbehalf@manuscriptcentral.com>
Reply-To: advances@rsc.org
To: m.zakki.fahmi@fst.unair.ac.id, zakkifahmi@gmail.com

Wed, Sep 29, 2021 at 8:50 PM

29-Sep-2021

Dear Mr Fahmi:

Manuscript ID: RA-ART-08-2021-006148
TITLE: Naproxen release aspect from Boron-doped carbon nanodots as bifunctional agent on cancer therapy

Thank you for your submission to RSC Advances, published by the Royal Society of Chemistry. I sent your manuscript to reviewers and I have now received their reports which are copied below.

I have carefully evaluated your manuscript and the reviewers' reports, and the reports indicate that major revisions are necessary.

Both reviewers requested additional characterization of the materials. Completely and unequivocally characterization of novel materials is a Journal requirement. The original Figures of microscopy must be supplemented.

Please submit a revised manuscript which addresses all of the reviewers' comments. Further peer review of your revised manuscript may be needed. When you submit your revised manuscript please include a point by point response to the reviewers' comments and highlight the changes you have made. Full details of the files you need to submit are listed at the end of this email.

Please submit your revised manuscript as soon as possible using this link:

*** PLEASE NOTE: This is a two-step process. After clicking on the link, you will be directed to a webpage to confirm. ***

https://mc.manuscriptcentral.com/rscadv?URL_MASK=7592d764471e4115b6da1a3692750cc4

(This link goes straight to your account, without the need to log on to the system. For your account security you should not share this link with others.)

Alternatively, you can log in to your account (<https://mc.manuscriptcentral.com/rscadv>) where you will need your case-sensitive user ID and password details.

You should submit your revised manuscript as soon as possible; please note you will receive a series of automatic reminders. If your revisions will take a significant length of time, please contact me.

Supporting our community through Covid-19

While our publishing services are running as usual, we also know that this is a very challenging time for everyone, for many different reasons. If any aspect of the publishing process is worrying you – for example you think you may struggle to meet a pre-determined deadline – please let us know, and we will work out an answer together.

All RSC Advances articles are published under an open access model, and the appropriate article processing charge (APC) will apply. Details of the APC and discounted rates can be found at <https://www.rsc.org/journals-books-databases/about-journals/rsc-advances/#charges-RSC-Advances>

RSC Advances strongly encourages authors of research articles to include an 'Author contributions' section in their manuscript, for publication in the final article. This should appear immediately above the 'Conflict of interest' and 'Acknowledgement' sections. I strongly recommend you use CRediT (the Contributor Roles Taxonomy from CASRAI, <https://casrai.org/credit/>) for standardised contribution descriptions. All authors should have agreed to their individual contributions ahead of submission and these should accurately reflect contributions to the work. Please refer to our general author guidelines <http://www.rsc.org/journals-books-databases/journal-authors-reviewers/author-responsibilities/> for more information.

The Royal Society of Chemistry requires the submitting author to provide their ORCID iD when they submit a revised manuscript. This is quick and easy to do as part of the revised manuscript submission process. We will publish this information with the article, and you may choose to have your ORCID record updated automatically with details of the publication.

Please also encourage your co-authors to sign up for their own ORCID account and associate it with their account on our manuscript submission system. Please note that we are unable to do this on behalf of your co-authors. For further information see: <https://www.rsc.org/journals-books-databases/journal-authors-reviewers/processes-policies/#attribution-id>.

I look forward to receiving your revised manuscript.

Associate Editor, RSC Advances

REVIEWER REPORT(S):

Referee: 1

Recommendation: Major revisions

Comments:

In this article, the researchers synthesized boron-carbon nanodots using the hydrothermal method. And according to the results of confocal and toxicity tests, boron-carbon nanodots have proven potential as candidates for bioimaging agents and naproxen delivery systems in HeLa cancer cells. The characterization data is not sufficient, and the description is not very convinced. Maybe we could considerate after major revision. Here are some detailed suggestions.

1. Please supplement SEM and TEM of BCD and N-BCD.
2. Please explain the peak at 1430 cm⁻¹ in FTIR spectra in Fig.3.
3. Please supplement the cell imaging of BCD in normal cells.
4. It is confusing, please explain about the following sentence in details based on the data, "The cell selectivity shown by the Boron-carbon nanodots sample is acceptable, which can be noticed from the image produced under X-ray radiation".
5. Please provide data to prove that the cell viability is above 80% with a concentration of 8111.97 µg/ml.
6. In this paper, BCD loaded with naproxen (N-BCD) was developed. The purpose is to deliver drugs. But the release amount of naproxen reached 80% at pH=7 within 3h, which showed that N-BCD was unstable under physiological conditions. Please provide data to prove that N-BCD can achieve the purpose of drug delivery.
7. All the caption of the figures is too simple, no detailed information. Please revise them according the published paper.
8. The quantum yield of 0.21% in conclusion is inconsistent with the body part.
9. The format of references should be unified. e.g. "African Health Sciences." should be modified to "Afr Health Sci" in the reference [49].

Additional Questions:

Does the work significantly advance the understanding or development in this field?: Yes

Is this work of relevance to the chemistry community?: Yes

Are the conclusions of the work convincing and sufficiently supported by experimental evidence?: No

Does the data provided fulfil the journal's data requirements?

See Journal specific guidelines: <https://www.rsc.org/journals-books-databases/about-journals/rsc-advances/#Characterisation-of-new-compounds>: Yes

Is the experimental section sufficiently detailed to allow others to reproduce the work?: No

Are the reported claims adequately discussed in the context of the literature?: Yes

Are the number of tables and figures in the manuscript appropriate and clear?: Yes

Referee: 2

Recommendation: Major revisions

Comments:

1. I suggest some more detailed experiments for the characterization of BCD. The STEM image and EDS elemental mapping analysis could be added.
2. The BCD seems to have agglomeration by photographs observations. How about the colloid stability of BCD? The long-term colloidal stability of the obtained BCD should be further studied.
3. Why can sialic acid receptors on HeLa cells allow BCD to specifically bind to the cytoplasm?
4. Why is the release efficiency in the first 20 minutes at pH 9 higher than that at pH 7?
5. What is the drug entrapment efficiency of BCD?
6. In conclusion section, the authors said "Boron-carbon nanodots have structural characteristics similar to an average particle size of 8.35 nm, the quantum yield of 0.21% has a B (OH) group that can bind specifically to cancer cells", it's not correspond to this work, please check it carefully.
7. Please check the reference session. For example, [25] J. Coates, Interpretation of Infrared Spectra A Practical Approach, Newtown, USA, 2006. [29] M. Z. Fahmi, J.-K. Chen, C.-C. Huang, Y.-C. Ling and J.-Y. Chang, J. Mater. Chem. B, 2015, 3, 5532-5543.

Additional Questions:

Does the work significantly advance the understanding or development in this field?: Yes

Is this work of relevance to the chemistry community?: Yes

Are the conclusions of the work convincing and sufficiently supported by experimental evidence?: No

Does the data provided fulfil the journal's data requirements?

See Journal specific guidelines: <https://www.rsc.org/journals-books-databases/about-journals/rsc-advances/#Characterisation-of-new-compounds>: Yes

Is the experimental section sufficiently detailed to allow others to reproduce the work?: No

Are the reported claims adequately discussed in the context of the literature?: Yes

Are the number of tables and figures in the manuscript appropriate and clear?: Yes

FILES TO PROVIDE WITH YOUR REVISED MANUSCRIPT:

IMPORTANT: Your original files are available to you when you upload your revised manuscript. Please delete any redundant files before completing the submission. Please carefully check the spelling and format of all author names, affiliations and funding information. If your paper is accepted for publication, it is important this information is accurate to ensure your article is correctly indexed, which may affect citations and future funding evaluation. Please note that if you have selected Accepted Manuscript publication, the author list will appear as provided in the ScholarOne submission details until your Advance Article is published and this information is updated from your article.

- A point-by-point response to the comments made by the reviewer(s)
- Your revised manuscript with any changes clearly marked (.doc(x) or .pdf file)
- Your revised manuscript as a .doc(x) file including figures, without highlighting, track changes, etc. (If providing in TeX format instead, please also provide a final PDF version including figures). Please note that we cannot proceed with publication using a .pdf file only.

High quality images

EITHER
embedded in a doc(x) file
OR
as separate numbered Figures, Schemes or Charts in .tif, .eps or .pdf format, with a resolution of 600 dpi or greater.

AND

- A table of contents entry: graphic maximum size 8 cm x 4 cm and 1-2 sentence(s) of editable text, with a maximum of 250 characters, highlighting the key findings of the work. It is recommended authors make use of the full space available for the graphic. See our Author Guidelines for more details: <https://www.rsc.org/journals-books-databases/author-and-reviewer-hub/>
- Your revised Electronic Supplementary Information (if any)
- Your revised CheckCIF reports (if any). Please ensure that any revised cif files have been deposited with the Cambridge Crystallographic Data Centre (CCDC) via <https://deposit.ccdc.cam.ac.uk/> before you submit your revised manuscript.

For Review-type articles only:

- A photograph and biography of yourself and your co-authors. Separate photographs of each author may be supplied or if you prefer, a group photograph, saved as a .tif, .pdf or .jpeg file. The resolution of the photographs should be 600 dpi or higher. The dimensions of the photograph in the printed journal will be 4 cm wide x 5 cm high (individual photograph) or 8.3 cm wide x 5 cm high (group photograph). Individual photographs should be accompanied by a maximum of 100 words; a group photograph by a maximum of 200 words. There can be a maximum of 6 individual biographies per article.
- Copies of permissions required from other publishers to reproduce figures. Please ensure that necessary permissions are acknowledged in the figure captions in accordance with the publishers' instruction. Information on how to obtain permissions and rights that we require are given on our website at <https://www.rsc.org/journals-books-databases/journal-authors-reviewers/licences-copyright-permissions/>

If you need to contact the journal, please use the email address advances@rsc.org

DISCLAIMER:

This communication is from The Royal Society of Chemistry, a company incorporated in England by Royal Charter (registered number RC000524) and a charity registered in England and Wales (charity number 207890). Registered office: Burlington House, Piccadilly, London W1J 0BA. Telephone: +44 (0) 20 7437 8656.

The content of this communication (including any attachments) is confidential, and may be privileged or contain copyright material. It may not be relied upon or disclosed to any person other than the intended recipient(s) without the consent of The Royal Society

of Chemistry. If you are not the intended recipient(s), please (1) notify us immediately by replying to this email, (2) delete all copies from your system, and (3) note that disclosure, distribution, copying or use of this communication is strictly prohibited.

Any advice given by The Royal Society of Chemistry has been carefully formulated but is based on the information available to it. The Royal Society of Chemistry cannot be held responsible for accuracy or completeness of this communication or any attachment. Any views or opinions presented in this email are solely those of the author and do not represent those of The Royal Society of Chemistry. The views expressed in this communication are personal to the sender and unless specifically stated, this e-mail does not constitute any part of an offer or contract. The Royal Society of Chemistry shall not be liable for any resulting damage or loss as a result of the use of this email and/or attachments, or for the consequences of any actions taken on the basis of the information provided. The Royal Society of Chemistry does not warrant that its emails or attachments are Virus-free; The Royal Society of Chemistry has taken reasonable precautions to ensure that no viruses are contained in this email, but does not accept any responsibility once this email has been transmitted. Please rely on your own screening of electronic communication.

More information on The Royal Society of Chemistry can be found on our website: www.rsc.org

Mochamad Zakki Fahmi <m.zakki.fahmi@fst.unair.ac.id>
To: aswandi wibrianto <aswandi.wibrianto-2016@fst.unair.ac.id>

Thu, Sep 30, 2021 at 1:42 PM

Aswandi ini ada review dr RSC Advance untuk komentar yang sulit saya yang handle

Best Regards,

Mochamad Zakki Fahmi, Ph.D (張家其)
Associate Professor, Department of Chemistry
Universitas Airlangga
Phone : +62-838-32901697
Email : m.zakki.fahmi@fst.unair.ac.id



[Quoted text hidden]

aswandi wibrianto <aswandi.wibrianto-2016@fst.unair.ac.id>
To: Mochamad Zakki Fahmi <m.zakki.fahmi@fst.unair.ac.id>

Thu, Sep 30, 2021 at 1:51 PM

Baik pak. Segera saya kerjakan. Terima kasih informasinya pak Zakki.

[Quoted text hidden]

aswandi wibrianto <aswandi.wibrianto-2016@fst.unair.ac.id>
To: Mochamad Zakki Fahmi <m.zakki.fahmi@fst.unair.ac.id>

Fri, Oct 1, 2021 at 4:38 PM

Dear Pak Zakki,


Berikut saya lampirkan revisi *manuscript*, *supporting information*, dan *response to reviewers*. Terima kasih banyak.


Regards,


Aswandi

[Quoted text hidden]

3 attachments

 **Responses_to_reviewers.docx**
130K

 **Electronics Supplementary Information 011021.docx**
1591K

 **Revised Manuscript 011021.docx**
8153K

Acknowledgement of your revised manuscript submission to RSC Advances - RA-ART-08-2021-006148.R1

1 message

RSC Advances <onbehalf@manuscriptcentral.com>

Wed, Oct 13, 2021 at 10:25 PM

Reply-To: advances@rsc.org

To: m.zakki.fahmi@fst.unair.ac.id, zakkifahmi@gmail.com

Cc: aswandi.wibrianto-2016@fst.unair.ac.id, M11006808@mail.ntust.edu.tw, dinar.fortuna.putri-2016@fst.unair.ac.id, satya.sakti@fst.unair.ac.id, leehweivoon@um.edu.my, m.zakki.fahmi@fst.unair.ac.id, zakkifahmi@gmail.com

13-Oct-2021

Dear Mr Fahmi:

TITLE: Naproxen release aspect from Boron-doped carbon nanodots as bifunctional agent on cancer therapy
AUTHORS: Wibrianto, Aswandi; Putri, Dinar Fortuna; Sakti, Satya Candara; Lee, Hwei Voon; Fahmi, Mochamad Zakki

Thank you for your revised submission to RSC Advances, published by the Royal Society of Chemistry. This is an automatic acknowledgement that you have uploaded your files to our online submission system. Your manuscript ID is: RA-ART-08-2021-006148.R1

Your manuscript will be passed to an editor for initial assessment as soon as possible. If there are any problems with your submission we will contact you.

All RSC Advances articles are published under an open access model, and the appropriate article processing charge (APC) will apply. Details of the APC and discounted rates can be found at <https://www.rsc.org/journals-books-databases/about-journals/rsc-advances/#charges-RSC-Advances>

Please indicate the above manuscript ID when you contact us about this submission.

If there have been any changes to the list of authors during this revision, please inform the Editorial Office of the reason for the change. All authors must confirm they are happy with the authorship change by emailing advances@rsc.org.

Do you have an ORCID iD? ORCID (Open Researcher and Contributor iD) is a unique researcher identifier that allows you to link your research output and other professional activities in a single record. We therefore encourage each researcher to sign up for their own ORCID account. Please edit your user account to link your ORCID iD or create a new one, ensuring that you have not linked your account to another researcher's ORCID iD. Please note that we are unable to do this on your behalf. If your article is accepted, you may choose to have your ORCID record updated automatically with details of the publication.

We already have the following information for authors of this manuscript: Wibrianto, Aswandi - <https://orcid.org/0000-0002-7746-7405>, Putri, Dinar Fortuna - No ORCID iD Available, Sakti, Satya Candara - No ORCID iD Available, Lee, Hwei Voon - <https://orcid.org/0000-0002-2997-5675>, Fahmi, Mochamad Zakki - <https://orcid.org/0000-0001-5430-9992>

If this is not how you want your name to appear on an Accepted Manuscript, please amend your ScholarOne account.

This journal has a policy of sharing reviewer reports. Please note that the Editor's decision and copies of the reports will be shared with all reviewers who provide a recommendation on your manuscript.

Please contact us if we can be of any assistance.

Yours sincerely,

RSC Advances Editorial Office

advances@rsc.org

If you need to contact the journal, please use the email address advances@rsc.org

DISCLAIMER:

This communication is from The Royal Society of Chemistry, a company incorporated in England by Royal Charter (registered number RC000524) and a charity registered in England and Wales (charity number 207890). Registered office: Burlington House, Piccadilly, London W1J 0BA. Telephone: +44 (0) 20 7437 8656.

The content of this communication (including any attachments) is confidential, and may be privileged or contain copyright material. It may not be relied upon or disclosed to any person other than the intended recipient(s) without the consent of The Royal Society of Chemistry. If you are not the intended recipient(s), please (1) notify us immediately by replying to this email, (2) delete all copies from your system, and (3) note that disclosure, distribution, copying or use of this communication is strictly prohibited.

Any advice given by The Royal Society of Chemistry has been carefully formulated but is based on the information available to it. The Royal Society of Chemistry cannot be held responsible for accuracy or completeness of this communication or any attachment. Any views or opinions presented in this email are solely those of the author and do not represent those of The Royal Society of Chemistry. The views expressed in this communication are personal to the sender and unless specifically stated, this e-mail does not constitute any part of an offer or contract. The Royal Society of Chemistry shall not be liable for any resulting damage or loss as a result of the use of this email and/or attachments, or for the consequences of any actions taken on the basis of the information provided. The Royal Society of Chemistry does not warrant that its emails or attachments are Virus-free; The Royal Society of Chemistry has taken reasonable precautions to ensure that no viruses are contained in this email, but does not accept any responsibility once this email has been transmitted. Please rely on your own screening of electronic communication.

More information on The Royal Society of Chemistry can be found on our website: www.rsc.org

Decision on submission to RSC Advances - RA-ART-08-2021-006148.R1

1 message

RSC Advances <onbehalf@manuscriptcentral.com>
Reply-To: advances@rsc.org
To: m.zakki.fahmi@fst.unair.ac.id, zakkifahmi@gmail.com

Mon, Nov 1, 2021 at 8:11 PM

01-Nov-2021

Dear Mr Fahmi:

Manuscript ID: RA-ART-08-2021-006148.R1

TITLE: Naproxen release aspect from Boron-doped carbon nanodots as bifunctional agent on cancer therapy

Thank you for submitting your revised manuscript to RSC Advances. After considering the changes you have made, I am pleased to accept your manuscript for publication in its current form. I have copied any final comments from the reviewer(s) below.

You will shortly receive a separate email from us requesting you to submit a licence to publish for your article, so that we can proceed with publication of your manuscript.

All RSC Advances articles are published under an open access model, and the appropriate article processing charge (APC) will apply. Details of the APC and discounted rates can be found at <https://www.rsc.org/journals-books-databases/about-journals/rsc-advances/#charges-RSC-Advances>

I would like to offer my congratulations on the acceptance of your manuscript. If you would like us to promote your article on our Twitter account @RSCAdvances please fill out this form: <https://form.jotform.com/212705294847058>. Alternatively, if you would like your article to be considered for further promotion via our WeChat channels then please do let us know.

We are offering all corresponding authors who are not already members of the Royal Society of Chemistry one year's Affiliate membership. If you would like to find out more please email membership@rsc.org, including the promo code OA100 in your message.

Learn all about our member benefits at <https://www.rsc.org/membership-and-community/join/#benefit>

We will email you information on how to access your RSC Advances article proofs shortly.

As an author you are entitled to a 25% discount on books published by the Royal Society of Chemistry. To receive this discount, enter the promotional code JLTH25 when purchasing from our online bookshop (pubs.rsc.org/bookshop). Please contact booksales@rsc.org if you have any problems.

Discover more Royal Society of Chemistry author services and benefits here:

<https://www.rsc.org/journals-books-databases/about-journals/benefits-of-publishing-with-us/>

Thank you for publishing with RSC Advances, a journal published by the Royal Society of Chemistry – connecting the world of science to advance chemical knowledge for a better future

With best wishes,

Dr Camilla Abbehausen

Associate Editor, RSC Advances

REVIEWER REPORT(S):
Referee: 2

Recommendation: Accept

Comments:

The authors have revised the manuscript strictly in the attached revised version. This manuscript can be accepted now.

Additional Questions:

Does the work significantly advance the understanding or development in this field?: Yes

Is this work of relevance to the chemistry community?: Yes

Are the conclusions of the work convincing and sufficiently supported by experimental evidence?: Yes

Does the data provided fulfil the journal's data requirements?

See Journal specific guidelines: https://www.rsc.org/journals-books-databases/about-journals/rsc-advances/#Characterisation-of-new-compounds: Yes

Is the experimental section sufficiently detailed to allow others to reproduce the work?: Yes

Are the reported claims adequately discussed in the context of the literature?: Yes

Are the number of tables and figures in the manuscript appropriate and clear?: Yes

If you need to contact the journal, please use the email address advances@rsc.org

DISCLAIMER:

This communication is from The Royal Society of Chemistry, a company incorporated in England by Royal Charter (registered number RC000524) and a charity registered in England and Wales (charity number 207890). Registered office: Burlington House, Piccadilly, London W1J 0BA. Telephone: +44 (0) 20 7437 8656.

The content of this communication (including any attachments) is confidential, and may be privileged or contain copyright material. It may not be relied upon or disclosed to any person other than the intended recipient(s) without the consent of The Royal Society of Chemistry. If you are not the intended recipient(s), please (1) notify us immediately by replying to this email, (2) delete all copies from your system, and (3) note that disclosure, distribution, copying or use of this communication is strictly prohibited.

Any advice given by The Royal Society of Chemistry has been carefully formulated but is based on the information available to it. The Royal Society of Chemistry cannot be held responsible for accuracy or completeness of this communication or any attachment. Any views or opinions presented in this email are solely those of the author and do not represent those of The Royal Society of Chemistry. The views expressed in this communication are personal to the sender and unless specifically stated, this e-mail does not constitute any part of an offer or contract. The Royal Society of Chemistry shall not be liable for any resulting damage or loss as a result of the use of this email and/or attachments, or for the consequences of any actions taken on the basis of the information provided. The Royal Society of Chemistry does not warrant that its emails or attachments are Virus-free; The Royal Society of Chemistry has taken reasonable precautions to ensure that no viruses are contained in this email, but does not accept any responsibility once this email has been transmitted. Please rely on your own screening of electronic communication.

More information on The Royal Society of Chemistry can be found on our website: www.rsc.org

Decision on submission to RSC Advances - RA-ART-08-2021-006148.R1

1 message

RSC Advances <onbehalf@manuscriptcentral.com>
Reply-To: advances@rsc.org
To: m.zakki.fahmi@fst.unair.ac.id, zakkifahmi@gmail.com

Mon, Nov 1, 2021 at 8:11 PM

01-Nov-2021

Dear Mr Fahmi:

Manuscript ID: RA-ART-08-2021-006148.R1

TITLE: Naproxen release aspect from Boron-doped carbon nanodots as bifunctional agent on cancer therapy

Thank you for submitting your revised manuscript to RSC Advances. After considering the changes you have made, I am pleased to accept your manuscript for publication in its current form. I have copied any final comments from the reviewer(s) below.

You will shortly receive a separate email from us requesting you to submit a licence to publish for your article, so that we can proceed with publication of your manuscript.

All RSC Advances articles are published under an open access model, and the appropriate article processing charge (APC) will apply. Details of the APC and discounted rates can be found at <https://www.rsc.org/journals-books-databases/about-journals/rsc-advances/#charges-RSC-Advances>

I would like to offer my congratulations on the acceptance of your manuscript. If you would like us to promote your article on our Twitter account @RSCAdvances please fill out this form: <https://form.jotform.com/212705294847058>. Alternatively, if you would like your article to be considered for further promotion via our WeChat channels then please do let us know.

We are offering all corresponding authors who are not already members of the Royal Society of Chemistry one year's Affiliate membership. If you would like to find out more please email membership@rsc.org, including the promo code OA100 in your message.

Learn all about our member benefits at <https://www.rsc.org/membership-and-community/join/#benefit>

We will email you information on how to access your RSC Advances article proofs shortly.

As an author you are entitled to a 25% discount on books published by the Royal Society of Chemistry. To receive this discount, enter the promotional code JLTH25 when purchasing from our online bookshop (pubs.rsc.org/bookshop). Please contact booksales@rsc.org if you have any problems.

Discover more Royal Society of Chemistry author services and benefits here:

<https://www.rsc.org/journals-books-databases/about-journals/benefits-of-publishing-with-us/>

Thank you for publishing with RSC Advances, a journal published by the Royal Society of Chemistry – connecting the world of science to advance chemical knowledge for a better future

With best wishes,

Dr Camilla Abbehausen

Associate Editor, RSC Advances

REVIEWER REPORT(S):
Referee: 2

Recommendation: Accept

Comments:

The authors have revised the manuscript strictly in the attached revised version. This manuscript can be accepted now.

Additional Questions:

Does the work significantly advance the understanding or development in this field?: Yes

Is this work of relevance to the chemistry community?: Yes

Are the conclusions of the work convincing and sufficiently supported by experimental evidence?: Yes

Does the data provided fulfil the journal's data requirements?

See Journal specific guidelines: https://www.rsc.org/journals-books-databases/about-journals/rsc-advances/#Characterisation-of-new-compounds: Yes

Is the experimental section sufficiently detailed to allow others to reproduce the work?: Yes

Are the reported claims adequately discussed in the context of the literature?: Yes

Are the number of tables and figures in the manuscript appropriate and clear?: Yes

If you need to contact the journal, please use the email address advances@rsc.org

DISCLAIMER:

This communication is from The Royal Society of Chemistry, a company incorporated in England by Royal Charter (registered number RC000524) and a charity registered in England and Wales (charity number 207890). Registered office: Burlington House, Piccadilly, London W1J 0BA. Telephone: +44 (0) 20 7437 8656.

The content of this communication (including any attachments) is confidential, and may be privileged or contain copyright material. It may not be relied upon or disclosed to any person other than the intended recipient(s) without the consent of The Royal Society of Chemistry. If you are not the intended recipient(s), please (1) notify us immediately by replying to this email, (2) delete all copies from your system, and (3) note that disclosure, distribution, copying or use of this communication is strictly prohibited.

Any advice given by The Royal Society of Chemistry has been carefully formulated but is based on the information available to it. The Royal Society of Chemistry cannot be held responsible for accuracy or completeness of this communication or any attachment. Any views or opinions presented in this email are solely those of the author and do not represent those of The Royal Society of Chemistry. The views expressed in this communication are personal to the sender and unless specifically stated, this e-mail does not constitute any part of an offer or contract. The Royal Society of Chemistry shall not be liable for any resulting damage or loss as a result of the use of this email and/or attachments, or for the consequences of any actions taken on the basis of the information provided. The Royal Society of Chemistry does not warrant that its emails or attachments are Virus-free; The Royal Society of Chemistry has taken reasonable precautions to ensure that no viruses are contained in this email, but does not accept any responsibility once this email has been transmitted. Please rely on your own screening of electronic communication.

More information on The Royal Society of Chemistry can be found on our website: www.rsc.org